Aqueous Humor Liquid Biopsy Safe in Pediatric Retinoblastoma
WEDNESDAY, May 14, 2025 -- For pediatric patients with retinoblastoma, aqueous humor liquid biopsy via anterior chamber paracentesis is a safe and well-tolerated procedure, according to a study recently published online in Ophthalmology.
Douglas Chigane, M.D., from the Children's Hospital Los Angeles, and colleagues examined the safety profile of aqueous humor liquid biopsy in pediatric patients with retinoblastoma and retinoblastoma-simulating lesions in a retrospective multicenter study involving 1,203 paracentesis procedures performed on 484 eyes of 425 pediatric patients (352 with retinoblastoma and 73 with retinoblastoma-simulating lesions).
The researchers found one mild complication among 1,203 procedures, representing an overall complication rate of 0.08 percent. At a median follow-up of 16 months, no moderate or severe complications were observed, including vision, eye loss, extraocular tumor spread, or death. Across multiple centers, the procedure demonstrated an excellent safety profile, with no permanent adverse outcomes.
"Given the expanding role of aqueous humor liquid biopsy in retinoblastoma diagnosis and treatment, these findings are crucial for guiding clinicians and reassuring parents about the procedure's safety," the authors write. "As the field advances, aqueous humor liquid biopsy stands poised to revolutionize the approach to intraocular cancer, offering a minimally invasive, highly effective method for ongoing disease monitoring and personalized care."
Several authors disclosed ties to the biopharmaceutical and ophthalmology industries.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Cancer Survival Lower in Rural Areas
WEDNESDAY, Oct. 1, 2025 -- Five-year cancer survival rates for each stage of cancer (localized, regional, and distant) is lower in nonmetropolitan areas for Black and White...
Loss of Smell May Linger After COVID-19
WEDNESDAY, Oct. 1, 2025 -- Self-reported change or loss in smell or taste is an accurate signal of verified hyposmia after COVID-19, although there is also a high rate of hyposmia...
Elderly Patients Benefit From Screening Mammography
WEDNESDAY, Oct. 1, 2025 -- Patients with breast cancer diagnosed at 80 years of age or older who received screening mammography present with earlier-stage disease and have better...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.